Skip to main content
Coverage for your commercially insured patients


Joseph L
Actual Nurtec ODT Patient

*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed,
number one in new prescriptions, and more neurologists selected as brand of choice

Well tolerated for acute and 
preventive treatment

Most Common (≥2%) Adverse Events

 Percentage of patients 
that experienced nausea1-3

Acute (one 75 mg dose)

2%Nurtec ODT

0.4% Placebo

Preventive (75 mg dose every other day)


0.8% Placebo

Percentage of patients 
that experienced abdominal pain/dyspepsia1,3

Preventive (75 mg dose every other day)


0.8% Placebo

Well tolerated in
 preventive study
2% (n=7/370) 
 due to AEs3

Nurtec ODT was not associated with any serious treatment-related AEs in clinical trials.2,3

The transfer of rimegepant into breastmilk is low (<1%).

Long-term safety maintained through 52 weeks1

1798 patients were exposed to

>111,000 doses

of rimegepant4

Up to 18 doses of Nurtec ODT can be taken per month.1

A long-term open label safety study with 1800 patients evaluated rimegepant 75 mg dosed as needed for 52 weeks (N=1514) and dosed every other day plus as needed for 12 weeks (N=286).1,5

Long-term safety was maintained in the long-term open-label safety study1

1800 patients were given multiple doses of rimegepant 75 mg, as needed up to one dose per day, for up to 52 weeks1,6

Enrollment Groups6

History of Moderate to Severe Migraine

2-8 attacks/​month (n=1033)

9-14 attacks/​month (n=481)

4-14 attacks/​month (n=286)

Rimegepant Treatment6

52 weeks as needed up to 1x/daily dosing

Up to 12 Weeks fixed dosing EOD + PRN dosing

EOD: every other day; PRN: as needed6

Average of 7 .7 doses per 4 weeks/subject for up to 52 weeks (n=1800)6

The ODT and tablet formulations of rimegepant are bioequivalent.2

References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. 3. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7. 4. Data on File. RIM113. Pfizer Inc. 5. McGinley JS, L'Italien GJ, Thiry AC, et al. Rimegepant 75 mg results in reductions in monthly migraine days: Secondary analysis of a multicenter, open label, long‑term safety study of rimegepant for the acute treatment of migraine. Virtual Poster presented at: American Academy of Neurology 2020 Annual Meeting; 2020. 6. Croop R, Berman G, Kudrow D, et al. Long-term safety of rimegepant 75 mg for the acute treatment of migraine (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020.